文献速递艾滋病与性传播感染

乌干达实施多替拉韦的人群有效性:前瞻性观察性队列研究(DISCO)48周结果

Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results.
PubMed 文献 · J Infect Dis · 2024-01-01

本研究在乌干达公立诊所前瞻性观察500名≥18岁、从NNRTI方案转换为TLD的HIV感染者,随访48周。转换后48周94%(469/500)参与者病毒载量<200拷贝/mL,2%失访或死亡,仅2%(9/500)病毒载量>500拷贝/mL,未发现新发多替拉韦耐药,2%因不良事件停药。

要点

  • TLD转换后48周94%(469/500)参与者病毒载量<200拷贝/mL。
  • 仅2%(9/500)病毒载量>500拷贝/mL,未发现新发多替拉韦耐药。
  • 2%(9/500)因不良事件停用TLD,2%(11/500)失访或死亡。

核心结论

  • 高病毒抑制率、高耐受性和无新发耐药支持TLD作为该地区首选一线方案。

研究设计与样本

  • 前瞻性观察性队列研究,纳入500名≥18岁、从NNRTI为基础方案转换为TLD的HIV感染者,在转换当日及24周、48周随访。

主要发现

  • 转换后48周,94%(469/500)参与者仍在 care 且病毒载量<200拷贝/mL。
  • 2%(11/500)失访或死亡;仅2%(9/500)病毒载量>500拷贝/mL。
  • 未发现新发多替拉韦耐药;2%(9/500)因不良事件停用TLD。

临床怎么用

  • 原文结论支持TLD作为该地区首选一线方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tenofovir/lamivudine/dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen for people with HIV (PWH), including those who were previously virologically suppressed on nonnucleoside reverse transcriptase inhibitors (NNRTIs). We sought to estimate the real-world effectiveness of the TLD transition in Ugandan public-sector clinics. METHODS: We conducted a prospective cohort study of PWH aged ≥18 years who were transitioned from NNRTI-based ART to TLD. Study visits were conducted on the day of TLD transition and 24 and 48 weeks later. The primary end point was viral suppression (<200 copies/mL) at 48 weeks. We collected blood for retrospective viral load (VL) assessment and conducted genotypic resistance tests for specimens with VL >500 copies/mL. RESULTS: We enrolled 500 participants (median age 47 years; 41% women). At 48 weeks after TLD transition, 94% of participants were in care with a VL <200 copies/mL (n = 469/500); 2% (n = 11/500) were lost from care or died; and only 2% (n = 9/500) had a VL >500 copies/mL. No incident resistance to DTG was identified. Few participants (2%, n = 9/500) discontinued TLD due to adverse events. CONCLUSIONS: High rates of viral suppression, high tolerability, and lack of emergent drug resistance support use of TLD as the preferred first-line regimen in the region. CLINICAL TRIALS REGISTRATION: NCT04066036.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. McCluskey SM, Muyindike WR, Nanfuka V, et al. Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results. J Infect Dis. 2024. PMID: 38748986. doi:10.1093/infdis/jiae260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。